Nikhil Prasad Fact checked by:Thailand Medical News Team Nov 08, 2026 19 minutes ago
Four new studies are raising serious concerns about the safety of benzodiazepines, a widely prescribed group of medications used to treat anxiety, insomnia, seizures, and other conditions. The research links these commonly used drugs to several potentially serious health problems, including heart failure, worsening memory and thinking abilities, miscarriage during pregnancy, and dangerous falls and fractures among older adults.
Four new studies link benzodiazepine use to increased risks of heart failure, cognitive impairment, miscarriage, and
serious injuries among older adults.
Benzodiazepines include familiar medications such as diazepam, lorazepam, alprazolam, and clonazepam. These drugs work by slowing activity in the central nervous system, producing calming and sedative effects. Although they can provide important medical benefits, their effects on alertness, coordination, and brain function have long raised safety concerns.
The latest findings suggest that certain patient groups may face additional risks that deserve closer medical attention. Importantly, the studies identify associations rather than proving that benzodiazepines directly cause these complications.
Heart Failure Risks Increase Among Benzodiazepine Users
Researchers from Taipei Medical University in Taiwan conducted a systematic review and meta-analysis examining whether benzodiazepines increase cardiovascular risks, particularly among people receiving treatment for insomnia.
Published in Cardiovascular Toxicology, the investigation combined findings from 11 previous studies.
The researchers discovered that benzodiazepine users had a 41% higher relative risk of developing heart failure compared with people who did not use these medications.
They also identified a 29% higher relative risk of hospitalization related to heart failure.
Heart failure occurs when the heart cannot pump blood efficiently enough to meet the body's needs. Patients may experience breathlessness, persistent fatigue, swollen legs, and difficulty performing ordinary activities.
The researchers additionally compared benzodiazepines with other medications prescribed for insomnia, including Z-drugs, suvorexant, and certain antipsychotic medications.
Their analysis indicated that benzodiazepine users experienced higher rates of heart failure-related hospitalization than patients receiving these alternative treatments.
The association appeared particularly concerning among individuals with existing heart failure or elevated cardiovascular risk.
However, researchers emphasized that most available evidence came from observational studies. Differences in underlying illnesses, medication exposure, and patient characteristics could have influenced the findings.
Consequently, the results support greater caution when prescribing benzodiazepines to vulnerable cardiac patients but do not establish that these medications directly damage the heart.
Long-Term Use Linked to Poorer Thinking Abilities
A second investigation, published in BMC Psychiatry, examined cognitive functioning amo
ng people diagnosed with schizophrenia.
Researchers from Shanghai Jiao Tong University School of Medicine and Shanghai Mental Health Center in China analyzed information from 114 participants enrolled in the SALT-C research cohort between 2016 and 2019.
The participants were divided into two equally sized groups.
One group included 57 individuals who had never used benzodiazepines, while the other included 57 individuals who had received stable benzodiazepine treatment for at least 60 consecutive days.
The groups were comparable in age, sex, illness duration, antipsychotic medication use, and overall psychiatric symptom severity.
Researchers evaluated cognitive performance using the Montreal Cognitive Assessment, a commonly used screening test measuring memory, attention, language, visual understanding, and problem-solving abilities.
The findings revealed a notable difference. Long-term benzodiazepine users recorded an average cognitive score of just 16.02, compared with 19.33 among participants who had never used these medications.
This represented a difference of 3.31 points, indicating substantially poorer performance among long-term users.
The most pronounced difficulties involved visuospatial and executive functioning.
Visuospatial abilities help individuals understand where objects are positioned, interpret visual information, and navigate their surroundings.
Executive functioning involves planning activities, organizing information, making decisions, and solving everyday problems.
Impairment in these areas can interfere with activities such as managing appointments, following instructions, handling finances, and completing complicated tasks.
Interestingly, researchers found no statistically significant cognitive differences between participants taking lower and higher benzodiazepine doses.
This suggests that the observed association was not clearly dependent on dosage within the studied population.
Nevertheless, the investigation measured cognition at only one point in time. It could not determine whether cognitive difficulties existed before treatment began.
The relatively small sample and single-center design also limit how broadly the findings can be applied.
Pregnancy Research Identifies Elevated Miscarriage Risks
A third study, published in BMC Pregnancy and Childbirth, examined benzodiazepine exposure during pregnancy and its relationship with miscarriage.
Researchers from Hospices Civils de Lyon in France, working with collaborators including researchers affiliated with Canadian institutions, reviewed evidence from 10 previously published studies.
Their combined analysis found that benzodiazepine exposure during pregnancy was associated with a 68% higher relative risk of miscarriage compared with pregnancies without such exposure.
The researchers also examined individual medications to determine whether risks differed between drugs.
Seven benzodiazepines had information available from at least 100 exposed pregnancies.
The reported increases in miscarriage risk were:
• Clonazepam: 82%
• Diazepam: 70%
• Bromazepam: 55%
• Lorazepam: 48%
• Alprazolam: 48%
• Oxazepam: 48%
• Chlordiazepoxide: 42%
However, the associations involving bromazepam and chlordiazepoxide did not reach statistical significance, meaning chance could not be ruled out as an explanation.
Another important finding concerned medication dosage. Three studies investigated whether greater benzodiazepine exposure corresponded with higher miscarriage risks.
All three reported evidence suggesting that higher doses were associated with greater risk.
One investigation found that low-dose clonazepam exposure was associated with an 84% increase in miscarriage risk, while high-dose exposure was associated with approximately 4.5 times the odds of miscarriage.
These figures describe relative associations rather than the absolute probability that an individual pregnancy will end in miscarriage.
Researchers also cautioned that underlying anxiety, insomnia, other illnesses, and additional medications could influence pregnancy outcomes.
Five of the 10 included studies had a high risk of bias, while differences in miscarriage definitions and incomplete reporting of early pregnancy losses created further uncertainty.
Pregnant patients should therefore discuss medication decisions with their healthcare professionals rather than abruptly discontinuing prescribed treatment.
Older Adults Face Greater Dangers from Falls and Fractures
The fourth investigation, published in Medical Science, examined the relationship between benzodiazepines and physical injuries among older adults.
Researchers from Mazovian Brodnowski Hospital in Poland reviewed 21 previously published studies involving geriatric patients.
Their findings indicated that benzodiazepine exposure was frequently associated with increased risks of falls and fractures.
Across the reviewed investigations, reported increases in fall risk ranged from approximately 40% to more than threefold, depending on the study population and methodology.
Fracture risks were also elevated, with reported increases ranging from approximately 20% to nearly fourfold.
One particularly concerning finding involved the period immediately after benzodiazepine treatment begins.
An included study reported approximately 3.79 times the odds of falling during the first 24 hours following treatment initiation.
This early vulnerability may reflect the medications' sedating effects, which can impair balance, coordination, alertness, and reaction times.
For older adults, even a seemingly minor fall can have devastating consequences. Hip fractures and other serious injuries may require hospitalization, surgery, prolonged rehabilitation, or permanent assistance with everyday activities.
Several reviewed studies additionally linked higher medication doses, longer treatment duration, and the simultaneous use of multiple medications with greater injury risks.
However, not every investigation identified significant associations. Studies involving hospitalized patients were less likely to demonstrate consistent increases.
Researchers acknowledged that differences in study designs, exposure periods, and injury definitions made direct comparisons difficult.
What These Findings Mean for Patients
Taken together, the four investigations highlight why benzodiazepine prescribing requires individualized assessment, particularly among patients with existing medical vulnerabilities.
As this
Thailand Medical News report highlights, the evidence spans several distinct patient populations and health outcomes, suggesting that medication safety should be evaluated beyond immediate symptom relief.
Importantly, the studies do not demonstrate that every benzodiazepine user will experience these complications.
Nor do they establish that benzodiazepines directly caused the reported outcomes.
Patients taking these medications regularly should consult their prescribing clinicians about treatment duration, dosage, potential alternatives, and whether continued use remains appropriate.
Suddenly stopping benzodiazepines after prolonged use can trigger withdrawal symptoms, including potentially dangerous seizures. Any reduction should therefore occur under medical supervision.
Conclusion
These four studies provide additional evidence that benzodiazepine use may carry important risks affecting cardiovascular health, cognitive functioning, pregnancy outcomes, and physical safety among older adults. Although observational findings cannot establish direct causation, the consistency of several reported associations warrants careful attention. Further research is needed to clarify underlying mechanisms, identify particularly vulnerable patients, and determine whether safer treatment strategies can reduce these complications without compromising necessary medical care.
The study findings were published in the peer reviewed journals: Cardiovascular Toxicology, BMC Psychiatry, BMC Pregnancy and Childbirth, and Medical Science.
Study Links:
https://link.springer.com/article/10.1007/s12012-026-10206-8
https://link.springer.com/article/10.1186/s12888-026-08210-x
https://link.springer.com/article/10.1186/s12884-025-08574-0
https://discoveryjournals.org/medicalscience/current_issue/v30/n167/e16ms3758.htm
Read Also:
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
